GEO Publications
Handout
NAR 2024 (latest)
NAR 2002 (original)
All publications
FAQ
MIAME
Email GEO
NCBI
>
GEO
>
Accession Display
Not logged in |
Login
GEO help:
Mouse over screen elements for information.
Scope:
Self
Platform
Samples
Series
Family
Format:
HTML
SOFT
MINiML
Amount:
Brief
Quick
GEO accession:
Sample GSM39442
Query DataSets for GSM39442
Status
Public on Apr 01, 2005
Title
ms122-3
Sample type
RNA
Source name
Staged C. elegans embryos
Organism
Caenorhabditis elegans
Extracted molecule
total RNA
Description
Mutant genotype mex-3(zu155); skn-1(RNAi) 122 minutes after the 4-cell embryonic stage at 22 degrees C
Sample_genotype: ms
Sample_time: 122
Submission date
Jan 24, 2005
Last update date
May 27, 2005
Contact name
Andrew Hill
E-mail(s)
andrew.hill@pfizer.com
Phone
617-674-6341
Organization name
Pfizer
Department
Research Business Technology
Street address
300 Technology Square
City
Cambridge
State/province
MA
ZIP/Postal code
02139
Country
USA
Platform ID
GPL200
Series (1)
GSE2180
C. elegans embryonic timecourse in wt and mutant embryos
Data table header descriptions
ID_REF
Affymetrix Qualifier
VALUE
RMA calulated using Bioconductor Affy package (http://www.bioconductor.org)
Data table
ID_REF
VALUE
171720_x_at
4.08425964788224
171721_x_at
5.83761901655124
171722_x_at
6.78116979689783
171723_x_at
3.42850856906959
171724_x_at
5.12679036670188
171725_x_at
4.28880212910854
171726_x_at
4.69189640825826
171727_x_at
3.141125882335
171728_x_at
3.48061677369028
171729_x_at
6.7208023653261
171730_x_at
2.73383383585120
171731_x_at
8.01344379508654
171732_x_at
6.37762181407695
171733_x_at
6.37831718864067
171734_x_at
9.53064659375037
171735_x_at
3.18109605589721
171736_x_at
8.40086825652627
171737_x_at
6.62786314826106
171738_x_at
4.02287062324018
171739_x_at
3.49401553376338
Total number of rows:
22625
Table truncated, full table size
608 Kbytes
.
Supplementary file
Size
Download
File type/resource
GSM39442.CEL.gz
2.5 Mb
(ftp)
(http)
CEL
GSM39442.EXP.gz
242 b
(ftp)
(http)
EXP
|
NLM
|
NIH
|
GEO Help
|
Disclaimer
|
Accessibility
|
